Influx Healthtech Q4 FY26 Share Price & Earnings Call Analysis
- Market cap
- ₹604 Cr
- P/E
- 31.58
- ROE
- 27.93%
- PEG
- 0.83
- Price to sales
- 4.11
- Debt to equity
- 0.00
- 52W high / low
- ₹312 / ₹175
- EBITDA margin
- 20.34%
- Net profit margin
- 13.02%
- Promoter holding
- 73.53%
- Sales (last year)
- ₹147 Cr
Guidance scorecard · Q4 FY26 call
What Influx Health.'s management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ4 FY26 call
20–40%- Influx Healthtech targets a minimum growth of 25% to 30% in FY '27, with ambitions to surpass this range, potentially reaching 35% to 40% based on past achievements.
- The company anticipates steady capacity utilization growth, with new plants expected to be operational around August, contributing approximately INR 40-50 crores in H2 FY '27.
- The veterinary segment and pet care market are expected to grow significantly, with capacity increasing from 150 kg/hour to around 1000 kg/hour (an 8x increase), gradually improving margins.
- Export revenues currently contribute around 15-20%, with an expected annual increase of 5-7% in export quantum.
2 more points from Influx Health.'s call on revenue
Create a free account to keep reading this call
MarginsQ4 FY26 call
FlatSee what Influx Health. said on margins — free account, 30 seconds.
CapexQ4 FY26 call
Planned- INR 13.84 crores of IPO proceeds allocated for capex utilized as of March 31, 2026.
- Board approved reallocation of INR 10 crores from veterinary, home care, and cosmetic divisions to expand nutraceutical CDMO facility.
- New facility (~75,000 sq. ft.) commissioning expected by July/August 2026, capacity to be 2.5x existing, targeting INR 450-500 crores revenue in a few years.
- Installed a new granulation line with ~480 kg/day capacity (24,000 bottles/day).
- Protein/snack bar segment growing strongly; pet food extrusion line ordered, capacity increasing from 100-150 kg/hr to 1000 kg/hr.
- Beverage segment building a canning facility and carbonated line; includes Tetra pack line booked.
- Investment in innovative packaging machinery (e.g., for cosmetics) imported.
2 more points from Influx Health.'s call on capex
Create a free account to keep reading this call
FundraisingQ4 FY26 call
None plannedSee what Influx Health. said on fundraising — free account, 30 seconds.
Order bookQ4 FY26 call
Rising- The company does not have long-term contracts typical in the industry, with some clients providing projections for 3 months to 1 year (e.g., Octavius has given a 1-year plan, Novus a 3-month projection).
- Existing clients are growing steadily and contributing to the order book; the top 50-100 clients remain largely the same.
- The new facility, equipped with more automated lines, is expected to serve larger clients, while the current facility will cater to medium and small clients.
- Capacity utilization is expected to build slowly and steadily; filling the new capacity will take time and is not expected immediately.
- The company anticipates regular growth of 25-30% year-on-year, inclusive of contributions from the new facility.
2 more points from Influx Health.'s call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Influx Health..
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Influx Health.
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Influx Health.
Quarterly Results
Quarter-by-quarter operating performance
Financials of Influx Health.
Profit & Loss
Annual income statement trend
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales + | 0 | 59 | 76 | 100 | 105 | 147 |
| Expenses + | 0 | 53 | 65 | 83 | 84 | 117 |
| Operating Profit | 0 | 6 | 11 | 17 | 21 | 30 |
| OPM % | 11% | 14% | 17% | 20% | 20% | |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 2 | 3 | 4 |
| Profit before tax | 0 | 6 | 10 | 15 | 18 | 27 |
| Tax % | 26% | 26% | 25% | 25% | 25% | |
| Net Profit + | 0 | 4 | 7 | 11 | 13 | 21 |
| EPS in Rs | 0.00 | 1,800.00 | 2,880.00 | 4,452.00 | 7.37 | 8.87 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Financials of Influx Health.
Balance Sheet
Capital structure and asset base
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 0.03 | 0.03 | 18 | 23 |
| Reserves | 0 | 4 | 12 | 23 | 18 | 78 |
| Borrowings + | 0 | 1 | 1 | 0 | 0 | 0 |
| Other Liabilities + | -0 | 12 | 16 | 18 | 34 | 23 |
| Total Liabilities | 0 | 18 | 28 | 41 | 70 | 124 |
| Fixed Assets + | 0 | 3 | 6 | 14 | 19 | 28 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 2 |
| Other Assets + | 0 | 15 | 22 | 27 | 52 | 90 |
| Total Assets | 0 | 18 | 28 | 41 | 70 | 124 |
Financials of Influx Health.
Cash Flows
Operating, investing and financing cash movement
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 4 | 7 | 9 | 7 | 4 |
| Cash from Investing Activity + | 0 | -3 | -5 | -8 | -9 | -25 |
| Cash from Financing Activity + | 0 | 1 | 0 | -1 | -0 | 45 |
| Net Cash Flow | 0 | 1 | 2 | 0 | -2 | 23 |
| Free Cash Flow | 0 | 1 | 2 | 1 | -1 | -21 |
| CFO/OP | 89% | 87% | 70% | 56% | 41% |
Financials of Influx Health.
Ratios
Working capital efficiency and return ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 64 | 66 | 58 | 113 | 84 | |
| Inventory Days | 14 | 18 | 41 | 112 | 67 | |
| Days Payable | 88 | 123 | 106 | 248 | 80 | |
| Cash Conversion Cycle | -10 | -39 | -6 | -24 | 71 | |
| Working Capital Days | 2 | 1 | 15 | 46 | 83 | |
| ROCE % | 237% | 111% | 85% | 60% | 40% |
Guidance history
How Influx Health.'s guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q4 FY26 call → | 20–40% | Flat | Planned | None planned | Rising |
| Q2 FY26 call → | 40%+ | Flat | Planned | — | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
62 out of 100 — Steady
Over the past year its share price has moved roughly in the middle of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +49.0% | 85% |
| Last 6 months | −3.0% | 48% |
| Last 3 months | −8.6% | 44% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Influx Health.: 0.4 × 85 + 0.4 × 48 + 0.2 × 44 = 62.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Influx Health.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY